Experts, FDA Debate Mortality as Endpoint for Multi-Cancer Diagnostic Trials

At an FDA advisory committee convened to gather insights on multi-cancer diagnostic (MCD) tests, the 10-member advisory panel veered off course when the topic of endpoints arose, voicing varying levels of support for mortality endpoints in trial design.
Source: Drug Industry Daily